Concepedia

Tianyuan Zhou

TZ

Statistics

Publications

22

Citations

2.1K

H-Index

18

Active since

2000

Affiliations

Ionis Pharmaceuticals (United States)(Current)

Janssen (United States)

Case Western Reserve University

University of California San Diego

University School

Tianyuan Zhou is an author at Ionis Pharmaceuticals (United States) specializing in oncology, molecular oncology, and molecular biology.

ORCID

Publications per year

2000–2023

22

Publications

22

AZD9150, a next-generation antisense oligonucleotide inhibitor of <i>STAT3</i> with early evidence of clinical activity in lymphoma and lung cancer

David S. Hong, Razelle Kurzrock, Youngsoo Kim et al. · Science Translational Medicine · 2015 · 440 citations · Full text

, , +8

SMRT-mediated repression of an H3K27 demethylase in progression from neural stem cell to neuron

Kristen Jepsen, Derek Solum, Tianyuan Zhou et al. · Nature · 2007 · 404 citations

, , +16

STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial

Matthew J. Reilley, Patricia McCoon, Carl Cook et al. · Journal for ImmunoTherapy of Cancer · 2018 · 288 citations · Full text

, , +13

Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell Growth

Yoshiaki Yamamoto, Yohann Loriot, Eliana Beraldi et al. · Clinical Cancer Research · 2015 · 124 citations

, , +17

Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells

Aditi Shastri, Gaurav S. Choudhary, Margarida Teixeira et al. · Journal of Clinical Investigation · 2018 · 93 citations · Full text

, , +17

1–5 of 22